Pharmaceutical Pricing & Market Access Expertise. For Germany embedded in Europe.

Services
Interim Management

Industry expertise that matters.

  • Dear colleagues, (future) business partners,

    We are very pleased to announce the founding of AccessMatters GmbH. The launch of our joint venture fills us with both great enthusiasm and a sense of awe as we face the market access challenges we aim to tackle together with you.

    We firmly believe that market access must be viewed broadly and that a holistic perspective on the diverse and complex issues involved can be an integral part of a company’s success. Thus, we share with you our industry experience and understanding of what drives teams and leaders, expert knowledge on specialized topics arising from the numerous healthcare policy changes of recent years, and, most importantly, a foundation of expertise, analytical skills, strategic acumen, and an entrepreneurial perspective.

    Having worked for years across the entire lifecycle of our products and viewing this as the central starting point for our services, we are pleased to offer tailored strategies and practical solutions in the areas of pharmaceutical market access, reimbursement, HTA, and pricing in Germany—all embedded within European and global commercial business strategy.

    Our promise:

    Scientifically sound strategies and actionable solutions

    Efficient work and a pragmatic approach, with the utmost focus on your projects and timelines. ​

    A strong professional network in Germany that connects you with decision-makers and experts. ​

    We look forward to working on many projects together!

    Lina Hohmann & Mona Glogger

Colleagues & clients we work with.

  • "Mona offers profound and deep knowledge in market access and pricing that truly makes a difference. Having personally executed price negotiations in Germany, she can early assess opportunities and pricing potential, thinking from the end. Her professional attitude, combined with her ability to add real value, makes working with her both enriching and genuinely enjoyable."

    — Martin Völkl

    Vice President/ General Manager Germany

    Revolution Medicines

  • "In a constantly evolving environment and the high pressure on EU pricing you need professionals like Lina, who develop strategies to drive better outcomes and doesn´t apply historical patterns to this new access environment. Lina brings strong scenario planning expertise and develops robust, credible pricing strategies snd builds assumptions that stand up to scrutiny. She is a very reliable partner who consistently delivers value."

    —Thomas Heininger

    Finance Director Germany & UK

    Madrigal Pharmaceuticals

  • "Glogger Consulting can elevate the market access strategy and execution in Germany - Mona brings together

    1) real in-the-room pricing and access negotiation expertise, across diverse therapeutic areas, including cell therapies,

    2) rigorous scientific and commercial insight to shape early to late-stage clinical programs and

    3) inspiration to shape the access landscape with creative thinking to anticipate and solve complex situations, benefiting any German and Global Value, Access & Pricing teams.

    Mona is the adviser you want for any forward-looking Market Access team."

    — Filipe Rodrigues

    Global Commercial & Market Access Leader

    Ex-Celgene, Ex-BMS, ex-AbbVie

  • "Mona is consistently pragmatic, solution-driven and reliable. Providing clear and effective results with a touch of finesse."

    — Lara Feghelm
    Global Compound Market Access Leader, Immunology

    Johnson & Johnson Innovative Medicines

  •  "I’ve had the pleasure of working with Lina on several Market Access projects, and her expertise and professionalism consistently stood out.

    Strategically, she has a deep understanding of the German AMNOG process, HTA frameworks, and pricing — always able to design sound Market Access strategies that drive clear value.

    Operationally, she impresses with her grasp of regional Market Access and her ability to turn strategy into day-to-day action through well-designed field implementation, training, and stakeholder engagement.

    Beyond her expertise, Lina is a trusted and inspiring colleague who approaches challenges with clarity, dedication, and genuine passion for what she does. Working with her has always been both insightful and a real pleasure and I warmly recommend it to anyone.”

    — Melanie Capewell

    Commercial Director, Head of Marketing and Sales Germany

    Madrigal Pharmaceuticals

  • “Mona Glogger is an outstanding market access consultant with deep expertise in the German healthcare system. She will play a pivotal role in shaping launch, pricing, and market access strategy, combining analytical rigor with practical, actionable insights. Her professionalism, responsiveness, and strategic mindset make her a highly valuable partner for any company seeking reliable, expert support in navigating the German market”

    —Steven Raemdonck

    Access, Pricing and Public Affairs Senior Director – EU & International Markets

    Idorsia Pharmaceuticals

  • "I had the pleasure of working closely with Lina at Celgene and then at BMS, and she is hands-down one of the most proactive and insightful Market Access professionals I´ve encountered, What sets Lina apart is her predictive accuracy; her assessment of value drivers and final pricing in the German market were constantly spot-on. Whether she was structuring complex dossiers or transitioning her expertise into the pricing department, her work was always high-impact and easy to navigate. For anyone looking for a consultant who truly understands the nuances of the German alndscape and can turn strategy into reality, I cannot recommend Lina high enough."

    —Alexandre Schiola

    Global Pricing & Access Strategy Team Lead

    Bristol Myers Squibb

News on German health policy changes.

Stay on top of the developments with us and find information on most important reforms here:

AMNOG 2.0. (2026): whats proposed

GKV-BStab Act 2026: what changes

Medical Research Act 2024: what changed

GKV-FinSta Act 2022: what changed

Because. Access. Matters.